JAZZ PHARMACEUTICALS PLC JAZZ
ASignal's systematic analysis rates JAZZ as Neutral.
Reflects the latest available analysis · analyzed Nov 5, 2026
The case on JAZZ
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin (91.10%) indicating pricing power
- Positive revenue growth (10.40% YoY)
- Free cash flow of $1.68B supports operational strength
- MACD histogram expanding, suggesting short-term momentum stabilization
- Forward P/E of 9.11x indicates potential valuation upside
- RSI at 66.8, approaching overbought territory
- MACD below signal line, indicating bearish momentum
- Current price above upper Bollinger Band (229.46), suggesting overextension
- Debt-to-equity ratio of 1.35x, above recommended threshold of 1.0
- Low ROE at 5.05%, indicating suboptimal capital efficiency
- No Reddit mentions, indicating low retail investor interest or visibility
See the full verdict on JAZZ
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes JAZZ
Most investors never get a second opinion, let alone several. ASignal runs JAZZ past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.